GHRP-2 vs PEG-MGF
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 2, Pralmorelin
GHRP-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of GHRP-6. It prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in Japan as a diagnostic agent for growth hormone deficiency. Outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound.
Also: Pegylated MGF, PEGylated Mechano Growth Factor
PEG-MGF is MGF (the synthetic E-domain peptide from the IGF-1Ec splice variant) with a polyethylene glycol chain attached to make it last longer in the body. That is the theory, anyway. We have to be blunt: there is essentially no published research on PEG-MGF itself. A 2026 clinical review of growth-axis peptides put it in its lowest evidence tier, with no peer-reviewed human studies and no published half-life. Everything said about it online is borrowed from MGF lab work, and MGF's own evidence is shaky.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- GHRP-2 has stronger research evidence (Human Trials) compared to PEG-MGF (Limited Research).
Detailed Comparison
| Attribute | GHRP-2 | PEG-MGF |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Like GHRP-6, GHRP-2 is an agonist at the ghrelin / growth hormone secretagogue receptor (GHS-R1a). Binding that receptor in the pituitary and hypothalamus drives a pulse of growth hormone release. It was designed to be more potent and somewhat cleaner than GHRP-6, with a milder effect on appetite, though it still acts on the ghrelin system so it is not free of off-target hormonal effects. Because it works upstream of the pituitary rather than replacing GH directly, the GH release it causes is still subject to the body's own feedback brakes such as somatostatin. | Pegylation is a real, well-understood drug technique: attaching PEG makes a molecule bigger, slows how fast the kidneys clear it, and shields it from enzymes. It works for approved drugs, and a pegylated version of full IGF-1 (a different molecule) showed a half-life of 140 to 200 hours in a 2017 first-in-human study. The pitch for PEG-MGF is that the same trick lets the short-lived MGF peptide circulate long enough to act on muscle throughout the body. But PEG also changes how a molecule binds and where it goes, so effects reported for unmodified MGF cannot simply be assumed to carry over. The 2026 review made exactly that point. And since the underlying MGF mechanism was not reproduced in a 2014 pharma study, PEG-MGF is a modification of a hypothesis. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | 200-400 mcg 2-3x per week (forum-reported) 2-3x weekly in forum protocols |
| Administration | Subcutaneous injection | Subcutaneous or intramuscular injection (forum-reported) |
| Typical Duration | 8-12 weeks | Forum protocols describe 8-16 week cycles with about 4 weeks off; no studied duration exists |
| Best Time to Take | Before bed or morning (fasted) | Not established (forums suggest post-workout) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-2 has genuine human data behind its diagnostic role. In Japan it reached phase II trials and was approved as pralmorelin (intravenous) to test for growth hormone deficiency, including in children with short stature, making it the only GH secretagogue in this class with any regulatory approval. A published human pharmacology study detected unchanged GHRP-2 and its metabolite AA-3 in the urine of ten male volunteers given the drug intravenously, work driven largely by anti-doping testing because GHRP-2 is banned in sport. What it does NOT have is solid controlled-trial evidence for the body-composition, anti-aging, or recovery uses it is marketed for online. So the honest picture is a real, approved diagnostic tool in one country, with everything beyond that being off-label or unproven research use. | Searching PubMed for PEG-MGF returns essentially one relevant hit: a 2026 narrative review in Frontiers in Endocrinology (Dominikowski and colleagues) on performance peptides that target the GH and IGF-1 axis. It rated PEG-MGF tier D: no peer-reviewed human studies, no reported route of administration in clinical research, half-life not reported, and safety concerns that are theoretical (based on MGF's link to cancer-cell growth in lab studies). The doses that circulate come from bodybuilding forums, which the review summarized only so doctors can recognize what patients are doing, not as guidance. Everything else people cite is MGF research: cell and animal studies suggesting muscle and heart repair effects, plus a careful 2014 study by Fornaro and colleagues that found no effect of MGF on muscle cells, and no effect of native or stabilized MGF on a separate signaling readout in heart cells. If you are looking for evidence that PEG-MGF builds muscle in humans, it does not exist yet. |
Frequently Asked Questions: GHRP-2 vs PEG-MGF
What is the difference between GHRP-2 and PEG-MGF?
GHRP-2 is a growth hormone peptide that ghrp-2 (generic name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue and a second-generation cousin of ghrp-6. it prompts the pituitary to release growth hormone and is the one peptide in this family with an actual regulatory approval: it is licensed in japan as a diagnostic agent for growth hormone deficiency. outside that narrow diagnostic use it has no approval and is sold elsewhere only as a research compound. PEG-MGF is a growth hormone peptide that peg-mgf is mgf (the synthetic e-domain peptide from the igf-1ec splice variant) with a polyethylene glycol chain attached to make it last longer in the body. that is the theory, anyway. we have to be blunt: there is essentially no published research on peg-mgf itself. a 2026 clinical review of growth-axis peptides put it in its lowest evidence tier, with no peer-reviewed human studies and no published half-life. everything said about it online is borrowed from mgf lab work, and mgf's own evidence is shaky. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-2 or PEG-MGF?
Neither is universally "better" - the choice depends on your specific goals. GHRP-2 is typically used for growth hormone purposes, while PEG-MGF is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-2 and PEG-MGF be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-2 and PEG-MGF together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.